AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 27666002
Drug: Pre-treatment with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-treatment with ticagrelor (at least 1.5h before PCI)
Trial: 27666002
Drug: Control Group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control Group (ticagrelor administered immediately before PCI)
Trial: 27668024
Drug: Effervescent NAC
RxNorm normalized name: NAC
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Effervescent NAC tablets
Trial: 27668024
Drug: Oral solution
RxNorm normalized name: Oral Solution
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral solution NAC
Trial: 27669017
Drug: High-dose inactivated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose inactivated influenza vaccine (IIV-HD)
Trial: 27669017
Drug: Standard-dose inactivated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose inactivated influenza vaccine (SD)
Trial: 27669747
Drug: FPG target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FPG target ≤5.6 mmol/L
Trial: 27669747
Drug: FPG target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FPG target ≤6.1 mmol/L
Trial: 27669747
Drug: FPG target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FPG target ≤7.0 mmol/L
Trial: 27670519
Drug: Behavioural Couples
RxNorm normalized name: IMMUNOGLOBULIN G4-KAPPA/G4-LAMBDA, ANTI-(HOMO SAPIENS GPRC5D (G PROTEIN-COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D)), AND ANTI-(HOMO SAPIENS CD3E (CD3 EPSILON, LEU-4)), HUMANIZED AND CHIMERIC MONOCLONAL ANTIBODY, BISPECIFIC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioural Couples Therapy (BCT) involving the gambler and the CSO
Trial: 27670519
Drug: Cognitive-Behavioural Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-Behavioural Therapy (CBT) involving the gambler alone
Trial: 27671037
Drug: Value-based formulary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Value-based formulary which eliminates copayment for high-value preventive medications
Trial: 27671037
Drug: Comprehensive self-management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive self-management support program promoting health behavior change and medication adherence
Trial: 27671037
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of value-based formulary and self-management support program
Trial: 27672408
Drug: Ingenol mebutate
RxNorm normalized name: Ingenol Mebutate
DrugBank: Ingenol mebutate (DB05013)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ingenol mebutate 0.05% gel after cryosurgery
Trial: 27676257
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral emtricitabine-tenofovir disoproxil fumarate PrEP administered through daily directly observed therapy (DOT) for ten consecutive days.
Trial: 27677166
Drug: Lower serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower serum albumin (per 0.5 g/dl decrease)
Trial: 27677442
Drug: Lower consumption
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower consumption frequencies of butter, cream cake, French fries, or high-percentage alcoholic beverages.
Trial: 27678432
Drug: Atorvastatin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (5 mg or 10 mg, increased to up to 80 mg based on LDL-C levels)
Trial: 27678541
Drug: Human recombinant
RxNorm normalized name: Human recombinant AP
DrugBank: Recombinant human alkaline phosphatase (DB17672)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human recombinant alkaline phosphatase (recAP) 0.4 mg/kg
Trial: 27678541
Drug: Human recombinant
RxNorm normalized name: Human recombinant AP
DrugBank: Recombinant human alkaline phosphatase (DB17672)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human recombinant alkaline phosphatase (recAP) 0.8 mg/kg
Trial: 27678541
Drug: Human recombinant
RxNorm normalized name: Human recombinant AP
DrugBank: Recombinant human alkaline phosphatase (DB17672)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human recombinant alkaline phosphatase (recAP) 1.6 mg/kg
Trial: 27678541
Drug: Most efficacious
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Most efficacious dose of recAP (to be determined in Part 2)
Trial: 27678545
Drug: Whole soy
RxNorm normalized name: soy acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole soy replacement diet (4 servings of whole soy foods containing 25g soy protein daily, replacing red or processed meat and high fat dairy products)
Trial: 27680873
Drug: Conventional oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional oral glucocorticoid treatment
Trial: 27680875
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist (GnRHa) - leuprolide 3.75-mg administered for 4 weeks
Trial: 27681711
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of all three strategies
Trial: 27681866
Drug: Selumetinib 75
RxNorm normalized name: Sélumétinib
DrugBank: Selumetinib (DB11689)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Selumetinib 75 mg daily with sorafenib 400 mg twice daily
Trial: 27683610
Drug: Control (other
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (other FDA-approved PAH therapies)
Trial: 27686833
Drug: JE-CV vaccine
RxNorm normalized name: Japanese encephalitis virus vaccine Nakayama-NIH strain, inactivated Injectable Suspension [Je-Vax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JE-CV vaccine in MBDV-primed 2-5-year-olds (n=78)
Trial: 27686833
Drug: JE-CV vaccine
RxNorm normalized name: Japanese encephalitis virus vaccine Nakayama-NIH strain, inactivated Injectable Suspension [Je-Vax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JE-CV vaccine in JE-vaccine-naïve toddlers
Trial: 27687127
Drug: 1.2 g
RxNorm normalized name: Humidifier 1.2 gallon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.2 g eicosapentaenoic acid + docosahexaenoic acid per day during low-fat diet phase
Trial: 27687127
Drug: 1.2 g
RxNorm normalized name: Humidifier 1.2 gallon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.2 g eicosapentaenoic acid + docosahexaenoic acid per day during habitual diet phase
Trial: 27690095
Drug: Conventional vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional vitamin D treatment (0.25 mcg alfacalcidol plus placebo 3×/week)
Trial: 27690095
Drug: Intensive vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive vitamin D treatment (0.25 mcg alfacalcidol 3×/week plus 50,000 IU ergocalciferol 1×/week)
Trial: 27692306
Drug: Direct oral
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct oral factor Xa inhibitors (rivaroxaban, apixaban, edoxaban)
Trial: 27692306
Drug: Direct oral
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct oral factor Xa inhibitors
Trial: 27692920
Drug: Intra-prostatic boost
RxNorm normalized name: Sus scrofa prostate preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-prostatic boost dose of 68 Gy
Trial: 27693556
Drug: selinexor and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: selinexor and related SINE compounds
Trial: 27693614
Drug: Cognitive-Behavioral Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-Behavioral Treatment (FFS/CBT)
Trial: 27694141
Drug: HIF-2α inhibition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIF-2α inhibition by small hairpin RNA or selective small molecule antagonist
Trial: 27699253
Drug: Oral ruxolitinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ruxolitinib
Trial: 27699634
Drug: Intravenous plasma-derived,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous plasma-derived, pasteurized, nanofiltered C1-inhibitor concentrate (pnfC1-INH; Berinert)
Trial: 27701169
Drug: Treatment time
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment time allocation
Trial: 27703758
Drug: Remote cognitive-behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remote cognitive-behavioural therapy (CBT) - 6-12 sessions
Trial: 27704266
Drug: Lenvatinib 12
RxNorm normalized name: lenvatinib 12 MG Daily Dose 30 Day Supply Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenvatinib 12 mg once daily (QD)
Trial: 27707765
Drug: STEBVax (recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: STEBVax (recombinant staphylococcal enterotoxin B protein vaccine) at doses ranging from 0.01 μg to 20 μg
Trial: 27707765
Drug: STEBVax (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: STEBVax (2.5 μg to 20 μg)
Trial: 27708788
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of LLLT and lorcaserin
Trial: 27709460
Drug: Concurrent treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent treatment with the proton pump inhibitor pantoprazole (DE-P)
Trial: 27709460
Drug: Overall effectiveness
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall effectiveness using either strategy or a combination
Trial: 27710003
Drug: FORNET (forensic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FORNET (forensic offender rehabilitation narrative exposure therapy)
Trial: 27712711
Drug: RESQ-eD (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RESQ-eD (twice daily for 7 days)
Trial: 27713637
Drug: Sunitinib at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib at a starting dose of 50 mg/day on a 4-weeks-on/2-weeks-off schedule
Trial: 27714595
Drug: Calcipotriol 50
RxNorm normalized name: Calcipotriol 50 microgram/g cutaneous cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcipotriol 50 µg/g and Betamethasone 0.5 mg/g aerosol foam
Trial: 27716218
Drug: Community-based football
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community-based football (one hour twice weekly for six months)
Trial: 27716304
Drug: 20,000 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20,000 IU vitamin D daily for 14 days followed by 10,000 IU per day for 7 days
Trial: 27716377
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of clinical parameters and biomarker concentrations
Trial: 27716819
Drug: Nintedanib (100,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nintedanib (100, 150, and 200 mg orally twice daily) combined with low-dose cytarabine (20 mg subcutaneous injection twice daily for 10 days)
Trial: 27716819
Drug: Nintedanib combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nintedanib combined with low-dose cytarabine (LDAC)
Trial: 27717384
Drug: Cleveland-Clinic Acute
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cleveland-Clinic Acute Renal Failure (CC-ARF) score
Trial: 27719673
Drug: Knowledge of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Knowledge of aetiology, diagnosis, and treatment of pre-eclampsia and eclampsia among health care providers.
Trial: 27719678
Drug: Administration of
RxNorm normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of antihypertensives and MgSO by some staff nurses.
Trial: 27720178
Drug: Plasma therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma therapy
Trial: 27723665
Drug: Non-VKA oral
RxNorm normalized name: Tavist Non-Sedating Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-VKA oral anticoagulants (NOACs)
Trial: 27724970
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g of tranexamic acid (TxA) administered after the first blood sample was taken.
Trial: 27725657
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (unmedicated)
Trial: 27726853
Drug: Intensification of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensification of medical therapy (initiation of aspirin or initiation/increases in dose of ACE inhibitors, ARBs, statins, or β blockers)
Trial: 27726853
Drug: No intensification
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No intensification of medical therapy
Trial: 27729313
Drug: Vemurafenib in
RxNorm normalized name: Product containing vemurafenib in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vemurafenib in combination with irinotecan and cetuximab
Trial: 27729766
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg ALA
Trial: 27729766
Drug: 1,200 mg
RxNorm normalized name: lecithin 1,200 mg ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,200 mg ALA
Trial: 27729766
Drug: Gastrointestinal prophylaxis
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gastrointestinal prophylaxis medications
Trial: 27730010
Drug: SAR422459 gene
RxNorm normalized name: Immature cell growth-inhibiting gene 1 protein
DrugBank: Cerliponase alfa (DB13173)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: SAR422459 gene therapy
Trial: 27733159
Drug: Statin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin therapy (moderate-intensity)
Trial: 27733243
Drug: Nivolumab 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab 3 mg/kg intravenously every 2 weeks until disease progression or treatment discontinuation
Trial: 27733374
Drug: Cisplatin 30
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 30 mg/m² weekly with concurrent standard radiotherapy (60-66 Gy over 6-7 weeks) and panitumumab.
Trial: 27733394
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D inadequacy (<50 nmol/L)
Trial: 27733413
Drug: Early oral
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early oral glucose tolerance test (OGTT) 75 g
Trial: 27733413
Drug: New screening
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New screening algorithm based on multivariable risk estimation using early OGTT 75 g and/or glyFn results
Trial: 27736729
Drug: KB004 (anti-EphA3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KB004 (anti-EphA3 monoclonal antibody) administered by intravenous infusion on days 1, 8, and 15 of each 21-day cycle in escalating doses.
Trial: 27736729
Drug: KB004 (anti-EphA3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KB004 (anti-EphA3 monoclonal antibody) administered by intravenous infusion.
Trial: 27740633
Drug: Epigenetic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epigenetic therapy (decitabine and panobinostat)
Trial: 27741195
Drug: Contraceptive implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contraceptive implants (34% of participants)
Trial: 27742908
Drug: Abiraterone acetate
RxNorm normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Abiraterone acetate (AA), 1,000 mg daily, and prednisone (P), 5 mg twice daily
Trial: 27747511
Drug: Methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate (MTX) dose 6-<8 mg/week in biologic-naïve patients
Trial: 27747511
Drug: Methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate (MTX) dose in biologic-exposed patients
Trial: 27747511
Drug: Increased MTX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased MTX doses
Trial: 27747515
Drug: TCZ 4
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: TCZ 4 mg/kg
Trial: 27747515
Drug: TCZ 8
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: TCZ 8 mg/kg
Trial: 27747585
Drug: Subcutaneous tocilizumab
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous tocilizumab (TCZ-SC) 162 mg weekly or every other week for up to 84 weeks
Trial: 27748745
Drug: Withdrawal of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withdrawal of PPARγ agonist rosiglitazone
Trial: 27749456
Drug: Bevacizumab 15
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab 15 mg/kg every 3 weeks with 4 to 8 cycles of paclitaxel plus carboplatin, continued until progression or for up to 24 months.
Trial: 27749456
Drug: Bevacizumab 15
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab 15 mg/kg for more than 15 months.
Trial: 27749456
Drug: Bevacizumab therapy
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab therapy beyond 15 months.
Trial: 27751676
Drug: Selumetinib, 75-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selumetinib, 75-mg single dose
Trial: 27751772
Drug: Antibiotic use
RxNorm normalized name: Antibiotics for systemic use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic use during travel
Trial: 27751941
Drug: fMRI data
RxNorm normalized name: NO DATA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fMRI data preparation techniques
Trial: 27752787
Drug: Preoperative mFOLFOX6
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative mFOLFOX6 therapy (6 cycles)
Trial: 27756258
Drug: Standard cytotoxic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard cytotoxic treatment
Trial: 27756308
Drug: Trimethoprim-sulfamethoxazole (TS)
RxNorm normalized name: sulfamethoxazole / trimethoprim
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim-sulfamethoxazole (TS) prophylaxis, daily from 6 weeks of age until exclusion of HIV-infection after cessation of breastfeeding.
Trial: 27757709
Drug: No endothelin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No endothelin receptor antagonists
Trial: 27760758
Drug: Blocking erythropoietin
RxNorm normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blocking erythropoietin (EPO)-EPO receptor (R) signaling
Trial: 27760761
Drug: Triplex vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triplex vaccine (MVA encoding CMV antigens)
Trial: 27761518
Drug: mHealth intervention
RxNorm normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mHealth intervention (self-monitoring via daily text messages, wireless devices for weight and steps tracking, 4 motivational interviewing-based phone sessions)
Trial: 27762283
Drug: HCV RNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCV RNA cutoff of 6 million IU/mL
Trial: 27763941
Drug: Selective serotonin
RxNorm normalized name: Selective serotonin (5HT1) agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective serotonin reuptake inhibitors (SSRI) treatment with citalopram
Trial: 27764686
Drug: Durvalumab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab (10 mg/kg every 2 weeks via intravenous infusion) with concurrent palliative RT
Trial: 27765757
Drug: mFOLFOX6 plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mFOLFOX6 plus ramucirumab (8 mg/kg)
Trial: 27765906
Drug: Targeted therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted therapy proposed to patients (clinical trial or registered drugs)
Trial: 27765906
Drug: Targeted treatment
RxNorm normalized name: benzoyl peroxide 25 mg in 1 mL TOPICAL SWAB [SkinPharmacy Advanced Acne Therapy Targeted Treatment Wipes]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted treatment received
Trial: 27765906
Drug: Genomic-driven treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genomic-driven treatment implementation
Trial: 27766119
Drug: Trial medication
RxNorm normalized name: benzoyl peroxide Medicated Pad [Triaz]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trial medication (levothyroxine) for 24 weeks
Trial: 27766602
Drug: Gene-Eden-VIR/Novirin (1-4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gene-Eden-VIR/Novirin (1-4 capsules per day for 2-48 months)
Trial: 27766602
Drug: Dose-response control
RxNorm normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dose-response control group
Trial: 27767222
Drug: Periodontal therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Periodontal therapy (mechanical debridement plus 1 week of amoxicillin/metronidazole)
Trial: 27767943
Drug: Equine-assisted occupational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Equine-assisted occupational therapy intervention
Trial: 27767943
Drug: Conventional treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatments (control group not explicitly mentioned)